Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Summit Therapeutics (SMMT) Net Margin (2022 - 2024)

Summit Therapeutics' Net Margin history spans 2 years, with the latest figure at 2021.89% for Q2 2024.

  • For Q2 2024, Net Margin changed N/A year-over-year to 2021.89%; the TTM value through Mar 2025 reached 6098.45%, up 231742.0%, while the annual FY2022 figure was 11174.75%, 627691.0% down from the prior year.
  • Net Margin reached 2021.89% in Q2 2024 per SMMT's latest filing, up from 1458.19% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 2021.89% in Q2 2024 to a low of 7700.0% in Q3 2022.